ArticleCirculation research2011
Insulin-like growth factor-1 receptor identifies a pool of human cardiac stem cells with superior therapeutic potential for myocardial regeneration.
Article in Circulation research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 115 citations in OpenAlex.
- Trial
- Retracted: Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial.Lancet (London, England) · 2011Trial
- Monoamine Oxidase-Dependent Pro-Survival Signaling in Diabetic Hearts Is Mediated by miRNAs.Cells · 2022Article
- Comparative proteomic analysis of nuclear and cytoplasmic compartments in human cardiac progenitor cells.Scientific reports · 2022Article
- Immunotherapy for Infarcts:BioResearch open access · 2020Article
- Definition of a cell surface signature for human cardiac progenitor cells after comprehensive comparative transcriptomic and proteomic characterization.Scientific reports · 2019Article
- Mesenchymal Stem Cell Therapy for Doxorubicin-Induced Cardiomyopathy: Potential Mechanisms, Governing Factors, and Implications of the Heart Stem Cell Debate.Frontiers in pharmacology · 2019Review
- Role of Insulin-like Growth Factor 1 Receptor Signaling in Stem Cell Stemness and Therapeutic Efficacy.Cell transplantation · 2018Review
- Insulin-like growth factor-1-mediated regulation of miR-193a expression promotes the migration and proliferation of c-kit-positive mouse cardiac stem cells.Stem cell research & therapy · 2018Article
- SDF1 gradient associates with the distribution of c-Kit+ cardiac cells in the heart.Scientific reports · 2018Article
- Molecular mechanisms of cardioprotective effects mediated by transplanted cardiac ckitOncotarget · 2018Article
- The Milk Thistle (Stem cells international · 2018Article
- Current Progress in the Rejuvenation of Aging Stem/Progenitor Cells for Improving the Therapeutic Effectiveness of Myocardial Repair.Stem cells international · 2018Review
- Bmi1 and BRG1 drive myocardial repair by regulating cardiac stem cell function in acute rheumatic heart disease.Experimental and therapeutic medicine · 2017Article
- Analysis of circulating microRNAs in patients with repaired Tetralogy of Fallot with and without heart failure.Journal of translational medicine · 2017Article
- Cardiac Nonmyocyte Cell Functions and Crosstalks in Response to Cardiotoxic Drugs.Oxidative medicine and cellular longevity · 2017Review
- Stem Cell Therapy for the Heart: Blind Alley or Magic Bullet?Journal of cardiovascular translational research · 2016Review
- Doxorubicin cardiotoxicity and target cells: a broader perspective.Cardio-oncology (London, England) · 2016Review
- Testosterone Antagonizes Doxorubicin-Induced Senescence of Cardiomyocytes.Journal of the American Heart Association · 2016Article
- Cellular and molecular characterization of human cardiac stem cells reveals key features essential for their function and safety.Stem cells and development · 2015Article
Corrections and comments
- Retraction · 2018-12-12Concerns/Issues about Data · Investigation by Company/Institution · Misconduct - Official Investigation(s) and/or Finding(s) · Upgrade/Update of Prior Notice(s) ·
- Correction · 2014-12-05Concerns/Issues about Image · Investigation by Company/Institution ·
- Expression of concern · 2018-11-20Concerns/Issues about Data · Investigation by Company/Institution · Misconduct - Official Investigation(s) and/or Finding(s) · Updated to Retraction ·
- Erratum issued
- Expression of concern
- Expression of concern
- Retracted
Authors and funding
18 authors at 2 institutions in 1 country.
Funding
Abstract
rationaleAge and coronary artery disease may negatively affect the function of human cardiac stem cells (hCSCs) and their potential therapeutic efficacy for autologous cell transplantation in the failing heart.
objectiveInsulin-like growth factor (IGF)-1, IGF-2, and angiotensin II (Ang II), as well as their receptors, IGF-1R, IGF-2R, and AT1R, were characterized in c-kit(+) hCSCs to establish whether these systems would allow us to separate hCSC classes with different growth reserve in the aging and diseased myocardium. METHODS AND
resultsC-kit(+) hCSCs were collected from myocardial samples obtained from 24 patients, 48 to 86 years of age, undergoing elective cardiac surgery for coronary artery disease. The expression of IGF-1R in hCSCs recognized a young cell phenotype defined by long telomeres, high telomerase activity, enhanced cell proliferation, and attenuated apoptosis. In addition to IGF-1, IGF-1R(+) hCSCs secreted IGF-2 that promoted myocyte differentiation. Conversely, the presence of IGF-2R and AT1R, in the absence of IGF-1R, identified senescent hCSCs with impaired growth reserve and increased susceptibility to apoptosis. The ability of IGF-1R(+) hCSCs to regenerate infarcted myocardium was then compared with that of unselected c-kit(+) hCSCs. IGF-1R(+) hCSCs improved cardiomyogenesis and vasculogenesis. Pretreatment of IGF-1R(+) hCSCs with IGF-2 resulted in the formation of more mature myocytes and superior recovery of ventricular structure.
conclusionshCSCs expressing only IGF-1R synthesize both IGF-1 and IGF-2, which are potent modulators of stem cell replication, commitment to the myocyte lineage, and myocyte differentiation, which points to this hCSC subset as the ideal candidate cell for the management of human heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.